Compare ProShares Ultra QQQ ETF (QLD) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares Ultra QQQ ETF vs Zimmer Biomet Holdings Inc — how do they compare? ProShares Ultra QQQ ETF trades at $98.22 (market cap $15.38B), while Zimmer Biomet Holdings Inc trades at $89.1 (market cap $16.95B). The key difference: ProShares Ultra QQQ ETF and Zimmer Biomet Holdings Inc are close in size by market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while ProShares Ultra QQQ ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold ProShares Ultra QQQ ETF for 37 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| QLD | ZBH | |
|---|---|---|
Market Cap | $15.38B | $16.95B |
Volume | 4,844,085 | 2,505,240 |
Sector | Leveraged / Inverse | Health |
52-Week High | $100.77 | $103.98 |
52-Week Low | $57.16 | $79.58 |
Typical Hold Time | 37 Days | 89 Days |
Enterprise Value | — | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QLD (ProShares Ultra QQQ ETF) trades at $98.12, down 2.11% on the day. Technical indicators show a bullish trend with moving averages supporting upside momentum while oscillators remain neutral. The ETF benefits from 2x leverage on the Nasdaq-100, providing amplified exposure to large-cap tech stocks. Recent institutional buying and media coverage highlight continued investor interest in leveraged tech exposure.
Outlook remains cautiously optimistic given the bullish technical setup and institutional accumulation, though leveraged ETFs carry elevated volatility risks during market downturns. The key opportunity lies in continued tech sector strength, while the primary risk involves amplified losses if the Nasdaq-100 declines significantly.
Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.07 surpassing the $2.01 estimate. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated to 9.48%. A quarterly dividend of $0.24 was declared, payable in October 2026. Analyst consensus price target is $103.11, implying potential upside from current levels.
The outlook is mixed: solid fundamentals and earnings momentum support long-term value, but technical weakness and elevated debt levels pose near-term risks. Investment appeal hinges on execution of commercial transformation and robotics adoption offsetting competitive pressures. Key risks include margin compression and macroeconomic sensitivity affecting procedure volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
